Data from Functional Restoration of BRCA2 Protein by Secondary <i>BRCA2</i> Mutations in <i>BRCA2</i>-Mutated Ovarian Carcinoma Article Swipe
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1158/0008-5472.c.6498885
· OA: W4392725861
<div>Abstract<p>Acquired platinum resistance is a serious problem in the treatment of ovarian carcinomas. However, the mechanism of the drug resistance has not been elucidated. Here, we show functional significance of restoration of BRCA2 protein by secondary <i>BRCA2</i> mutations in acquired drug resistance of <i>BRCA2</i>-mutated ovarian carcinoma. Three ovarian cancer cell lines (PEO1, PEO4, and PEO6) were derived from a <i>BRCA2</i> mutation [5193C>G (Y1655X)] carrier with ovarian carcinoma with acquired cisplatin resistance and a secondary <i>BRCA2</i> mutation [5193C>T (Y1655Y)] that canceled the inherited mutation. PEO1 was BRCA2 deficient and sensitive to cisplatin and a poly(ADP-ribose) polymerase inhibitor, AG14361, whereas PEO4 was resistant. PEO4 and PEO6, derived from ascites at the time of relapse with cisplatin resistance, had the secondary mutation and were BRCA2 proficient. <i>In vitro</i> cisplatin/AG14361 selection of PEO1 led to restoration of BRCA2 due to another secondary <i>BRCA2</i> mutation. BRCA2 depletion sensitized BRCA2-restored PEO1 clones and PEO4 to cisplatin/AG14361. Thus, restoration of BRCA2 due to secondary <i>BRCA2</i> mutation is involved in acquired drug resistance of <i>BRCA2</i>-mutated ovarian carcinoma. [Cancer Res 2009;69(16):6381–6]</p></div>
